# COVID Protection After Transplant-Immunosuppression Reduction

> **NCT05077254** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 48 (actual)

## Conditions studied

- Kidney Transplant Recipients
- Liver Transplant Recipients

## Interventions

- **BIOLOGICAL:** Pfizer-BioNTech COVID-19 Vaccine 2023-2024
- **BIOLOGICAL:** Moderna COVID-19 Vaccine 2023-2024
- **DRUG:** SOC IS Regimen
- **DRUG:** SOC IS Reduction

## Key facts

- **NCT ID:** NCT05077254
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-06
- **Primary completion:** 2024-02-28
- **Final completion:** 2025-02-21
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077254, "COVID Protection After Transplant-Immunosuppression Reduction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05077254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*